No Data
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
BofA Securities analyst Jason Zemansky maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Leerink Partners Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $13
Leerink Partners analyst Daina Graybosch maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and sets the target price at $13.According to TipRanks data, the analyst has a success rate of 31
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL) and Chimerix (CMRX)
Express News | Werewolf Therapeutics Inc : Leerink Partners Cuts Target Price to $13 From $15
Wedbush Adjusts Price Target on Werewolf Therapeutics to $8 From $9, Maintains Outperform Rating